Dysport
Phase 2Biologic
IpsenDysport is one of 22 biologic programs targeting Erythema. It is currently in Phase 2.
3
Indications
15
Total Trials
2
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Erythema
#DrugCompanyPhaseTrials
1Trexall
Jazz PharmaceuticalsApproved
Lamprene
NovartisApproved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Accutane
CConrado Roberto Hoffmann Filho
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Ceftin
GGlaxo Dba Glaxosmithkline
Approved
Plaquenil
Jazz PharmaceuticalsPreclinical
Dysport
IpsenPhase 2
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Advil
KKenvue Brands
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Spastic Cerebral Palsy1 trial
Dystonia1 trial
Abobotulinum Toxin and Neubotulinum Toxin Injection in Cerivical Dystonia
Completed·DDepartment of Medical Services Ministry of Public Health of Thailand·Phase 3·NCT03805152·52 enrolled
8 more indications
Skin Cancer1 trial
Cervical Dystonia1 trial
Cerebral Palsy1 trial
Effect of Dysport Injections on Energy Expenditure and Walking Efficiency in Children With Cerebral Palsy
Completed·—·Phase 3·NCT03469999·12 enrolled
Randomized Controlled Trial1 trial
Moderate to Severe Upper Facial Lines1 trial
Spasticity1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dysport. EMBL-EBI & Wellcome Sanger Institute.
- [4]